133 related articles for article (PubMed ID: 11501778)
1. Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer.
Tropé C; Kristensen G; Kisic J; Kaern J
Eur J Gynaecol Oncol; 2001; 22(3):223-7. PubMed ID: 11501778
[TBL] [Abstract][Full Text] [Related]
2. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
Pectasides D; Xiros N; Papaxoinis G; Aravantinos G; Sykiotis C; Pectasides E; Psyrri A; Koumarianou A; Gaglia A; Gouveris P; Economopoulos T
Gynecol Oncol; 2008 Jan; 108(1):47-52. PubMed ID: 17915300
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE
Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
[TBL] [Abstract][Full Text] [Related]
5. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
6. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
7. Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.
Tropé C; Hogberg T; Kaern J; Bertelsen K; Bjorkholm E; Boman K; Himmelmann A; Horvath G; Jacobsen A; Kuoppola T; Vartianen J; Lund B; Onsrud M; Puistola U; Salmi T; Scheistroen M; Sandvei R; Simonsen E; Sorbe B; Tholander B; Westberg R
Ann Oncol; 1998 Dec; 9(12):1301-7. PubMed ID: 9932160
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
Muggia FM; Hainsworth JD; Jeffers S; Miller P; Groshen S; Tan M; Roman L; Uziely B; Muderspach L; Garcia A; Burnett A; Greco FA; Morrow CP; Paradiso LJ; Liang LJ
J Clin Oncol; 1997 Mar; 15(3):987-93. PubMed ID: 9060537
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy.
Rosati G; Riccardi F; Tucci A; De Rosa P; Pacilio G
Tumori; 2000; 86(3):207-10. PubMed ID: 10939600
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.
Gordon AN; Granai CO; Rose PG; Hainsworth J; Lopez A; Weissman C; Rosales R; Sharpington T
J Clin Oncol; 2000 Sep; 18(17):3093-100. PubMed ID: 10963637
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
Miglietta L; Amoroso D; Bruzzone M; Granetto C; Catsafados E; Mammoliti S; Guarneri D; Pedulla F; Foglia G; Ragni N; Martini MC; Brema F; Addamo G; Moraglio L; Pastorino G; Boccardo F
Oncology; 1997; 54(2):102-7. PubMed ID: 9075779
[TBL] [Abstract][Full Text] [Related]
16. Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study.
Gebbia V; Di Marco P; Borsellino N; Gebbia N; Valerio MR; Fallica G; Tirrito ML; Valenza R; Citarrella P; Benedetti Panici P
Anticancer Drugs; 2003 Jun; 14(5):359-64. PubMed ID: 12782942
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy in recurrent epithelial ovarian cancer (EOC): an analysis of prognostic factors.
Shamsunder S; Kumar L; Gupta S; Kumar S; Bhatla N; Singh R; Kochupillai V
J Obstet Gynaecol Res; 2000 Jun; 26(3):215-22. PubMed ID: 10932985
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
Holmes FA; Valero V; Walters RS; Theriault RL; Booser DJ; Gibbs H; Fraschini G; Buzdar AU; Willey J; Frye D; Asmar L; Hortobagyi GN
Ann Oncol; 1999 Apr; 10(4):403-11. PubMed ID: 10370782
[TBL] [Abstract][Full Text] [Related]
19. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
20. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
Eur J Gynaecol Oncol; 1998; 19(1):5-10. PubMed ID: 9476049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]